Industry & Technology Transfer
In biotech, technology transfer is not a slogan: it is the ability to transform IP, processes and data into plants that produce, contracts that hold up and numbers that convince banks, partners and regulators. At Technoscience, we read industry and technology transfer as a whole: intellectual-property strategy and subsidised finance, open innovation guided by technical due diligence, scale-up with quality by design, supply chain and GMP compliance. This section shows how we support biotech technologies from patent to market, preventing a sound idea from being lost amid bureaucracy, weak contracts or unprepared plants.
A bridge between plants, IP and finance
In Industry & Technology Transfer provides pathways designed for those who need to make decisions about plants, IP, finance and partnerships, not for those seeking generic overviews. The focus is one thing: bringing biotech technologies from the laboratory to the factory with defensible figures and quality.
From IP to market: Patent Box, Smart&Start and biotech corporate financing explains how to turn intellectual property into an operational asset: IP strategy and freedom to operate, rigorous use of the Patent Box, integration of Smart&Start and subsidised finance into the technical roadmap, and a mixed equity–debt structure to finance plants, validation and initial production without allowing incentives to dictate the project.
Open Innovation in biotech: how to build effective partnerships goes into the substance of collaborations: when opening up makes sense, how to conduct technical due diligence that genuinely reduces uncertainty, how to design roles, IP (Background/Foreground), shared data, co-development/licensing/joint-venture models, and milestones with decision gates that allow a “Go” or “No-Go” without losing months.
From PoC to Scale-up: Quality, Supply Chain and Compliance is dedicated to the most delicate leap: from bench to plant. Here you will find how we set up the biotech scale-up with Quality by Design, DoE, CQAs/CPPs, PPQ, cleaning validation, data integrity, a “GMP-ready” supply chain and documentation that withstands an audit, linking yields, off-spec, batch-release times and energy per unit of product to economic KPIs.
When greater depth is needed on protection issues, the page “Intellectual Property in biotech: strategy, protection and value” explores choices between patents and trade secrets, FTO, contracts (MTA, NDA, licensing, research agreements), and the management of datasets and algorithms, so that IP genuinely becomes the supporting structure that convinces investors, industrial partners and regulators.
If you work in technical management, operations, quality, finance or business development in biotech, this section is designed to provide you with operational criteria on IP, plants, supply chain and financial instruments, showing how Technoscience can support you from the first term sheet through to the validation batch.
How to work with us: what is really needed at the outset
To assess a project in the Industry & Technology Transfer we ask for a number of concrete elements. First: the state of the intellectual property and the technical roadmap, from the PoC to the next development steps, expressed through a clear request (patent, licensing, scale-up, open innovation, funding). Second: the key figures – TRL, processes and CMC, plant requirements, estimated costs, any incentives already activated (Patent Box, calls for funding, Smart&Start) and the main perceived risks. Third: the industrial and regulatory context: target markets, partners involved, quality and compliance requirements. In return, we offer a technical-financial fit check that aligns IP, processes, quality and subsidised-finance instruments, and a credible TRL pathway from the protected idea to production, integrating Patent Box, open innovation and corporate financing where needed.
Choose Technoscience!
If you are developing a biotech or digital technology and want to understand how to turn it into an industrial project, use this form to request a fit check on IP, scale and finance. In a short call, we align patent and know-how status, technical maturity (TRL), plant/quality needs and financing options (incentives, equity, debt). If the foundation is solid, we jointly design a roadmap from R&D to manufacturing with technical, economic and regulatory milestones and a coherent financing structure. If critical elements are missing, we say so immediately, so you can decide whether to strengthen or resize the project before committing capital and reputation.
Frequently Asked Questions
The questions you ask us most often
It is an approach that defines the the actual biology of the disease (tissues, markers and omics profiles where indicated) and links it to diagnostic and therapeutic decisions diagnostic and therapeutic personalised. It does not stop at generic classifications or guidelines applied wholesale: it builds a individual pathway measurable through robust clinical endpoints.
We start from risk classification and by the clinical scope of use. Requirements, risk management, clinical evaluation, software validation where present, and a plan for post-market surveillance. Documentation accompanies the entire lifecycle; compliance is not an event, it is a process.
It means speaking the standard languages of the sector (e.g. HL7/FHIR), maintain stable mappings, guarantee import/export without lock-in, and allow clinicians to see the data within its context (EHR, LIS, PACS) without duplication or manual copying.
Data-driven platforms collect, normalise and interpret medical data from certified devices, turning raw signals into clinically useful information for prevention, diagnosis and continuous monitoring.
Certified medical devices such as portable ECGs, pulse oximeters, multisensor wearables and environmental sensors underpin reliable remote monitoring and proactive prevention, both in healthcare and in the workplace.
Informed consent specific and understandable, compliant data governance, measures for pseudonymisation/de-identification, safety plans and audit documented, controls on the pre-analytical and analytical phases, and a return-of-results plan of results where required. If the project leads to clinical decisions or regulated products, additional requirements apply (clinical evaluations, MDR, GCP), and must be integrated from the outset.
An enabling role. The biobanks ensure traceable and comparable samples; the omics broaden the understanding of the underlying mechanisms (inflammatory, metabolic and genetic). When integrated with rigorous protocols and real-world data, make reproducible the evidence and accelerate translation towards clinical trials or clinical adoption.
With privacy by design and security by design: data minimisation, encryption in transit and at rest, access control, environment segmentation, audit trails and incident-response procedures. Roles and legal bases are made explicit; suppliers are also assessed for business continuity.
Integrated platforms enable intelligent surveillance, anticipating clinical events through composite indices and predictive algorithms and facilitating timely, personalised interventions instead of fixed-interval checks.
The data collected undergo normalisation, quality verification and audit-trail processes; they are managed according to security and privacy protocols compliant with applicable regulations (such as the GDPR).
With a reasoned request that describes purposes, study design, ethical criteria and sample/data requirements. The competent committee assesses consistency, proportionality and impact. Access, when granted, is conditional with quality protocols, traceability of use and the return of outcomes needed to update the biobank’s knowledge base.